Loading...
XSTO
BIOVIC B
Market cap12mUSD
Dec 05, Last price  
0.55SEK
1D
-2.46%
1Q
-12.34%
IPO
-95.67%
Name

Biovica International AB

Chart & Performance

D1W1MN
XSTO:BIOVIC B chart
P/E
—
P/S
13.33
EPS
—
Div Yield, %
—
Shrs. gr., 5y
29.58%
Rev. gr., 5y
38.83%
Revenues
9m
+18.23%
4,045,026459,0002,432,000632,0002,723,0003,005,0001,671,0002,077,0002,045,0003,384,0007,290,0008,619,000
Net income
-88m
L-29.80%
-5,371,659-7,043,000-5,031,000-14,857,000-18,064,000-21,556,000-30,318,000-39,483,000-60,003,000-110,492,000-124,823,000-87,624,000
CFO
-85m
L-25.49%
0922,000-9,385,000-11,090,000-14,882,000-17,966,000-24,780,000-34,409,000-52,126,000-94,640,000-114,575,000-85,367,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Biovica International AB (publ), a biotechnology company, develops and commercializes blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in Sweden and internationally. It primarily focuses on breast cancer. The company develops DiviTum, a biomarker assay that measures the activity of the enzyme thymidine kinase-1 in blood serum or cell cultures. It serves cancer institutes, pharmaceutical companies, and collaborative groups. The company was incorporated in 2008 and is headquartered in Uppsala, Sweden.
URL
https://biovica.com/
IPO date
Mar 29, 2017
Employees
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑042024‑042023‑042022‑042021‑042020‑042019‑042018‑042017‑042016‑04
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT